Importance The benefits and harms of adding long-acting muscarinic antagonists (LAMAs)
to inhaled corticosteroids (ICS) and long-acting β 2-agonists (LABAs) for moderate to severe …

Conflicting evidence is currently available concerning the impact on asthma exacerbation of
triple inhaled corticosteroid (ICS)/long-acting β 2-adrenoceptor agonist (LABA)/long-acting …

Background Asthma affects 350 million people worldwide including 45% to 70% with mild
disease. Treatment is mainly with inhalers containing beta₂‐agonists, typically taken as …

Background Long‐acting beta 2‐agonists (LABA) in combination with inhaled
corticosteroids (ICS) are increasingly prescribed for children with asthma. Objectives To …

Background Long-acting ß 2-agonists (LABA) in combination with inhaled corticosteroids
(ICS) are increasingly prescribed in asthmatic children. Objectives To compare the safety …

Background Maintenance treatment with long‐acting beta 2‐agonists and inhaled
corticosteroids (LABA/ICS) can relieve asthma symptoms and reduce the frequency of …

Background Asthma patients who continue to experience symptoms despite taking regular
inhaled corticosteroids (ICS) represent a management challenge. Long‐acting beta2 …

Background Consensus statements recommend the addition of long‐acting inhaled ß2‐
agonists (LABA) only in asthmatic patients who are inadequately controlled on inhaled …

BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and
recent evidence suggested a detrimental effect on asthma control as well as an increased …

Importance Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to
inhaled corticosteroids in the management of persistent asthma. Objective To conduct a …